Abstracts tagged "safety and treatment"

Abstract Number: 1327 • 2018 ACR/ARHP Annual Meeting
The Effect of Etoposide on Inducing Remission in Refractory Adult-Onset Still’s Disease: A Retrospective, Single-Center Study
Haiting Wang¹, Xiaodong Wang¹, Ting Li¹ and Shuang Ye², ¹Department of Rheumatology, Renji Hospital South Campus, Shanghai Jiao Tong University School of Medicine, Shanghai, China, ²Rheumatology, Ren Ji Hospital, South Campus, School of Medicine, Shanghai Jiaotong University, Shanghai, China
Background/Purpose: Adult onset Still¡¯s disease (AOSD) is a rare inflammatory disorder of unknown etiology. Macrophage activation syndrome (MAS) is a life-threatening complication and has been…
Abstract Number: 2167 • 2017 ACR/ARHP Annual Meeting
Efficacy and Safety of Rituximab in Anti-Synthetase Positive and Negative Patients with Idiopathic Inflammatory Myopathy– a Registry-Based Study
Valérie Leclair, Maryam Dastmalchi, Angeles Shunashy Galindo-Feria and Ingrid E. Lundberg, Department of Medicine, Rheumatology Unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Rituximab (RTX) in idiopathic inflammatory myopathies (IIM) failed to show efficacy in the placebo-controlled Rituximab in Myositis (RIM) trial. However, post hoc analyses indicated…
Abstract Number: 509 • 2017 ACR/ARHP Annual Meeting
Long-Term Safety and Efficacy of Upadacitinib (ABT-494), an Oral JAK-1 Inhibitor in Patients with Rheumatoid Arthritis in an Open Label Extension Study
Mark C. Genovese¹, Joel Kremer², Sheng Zhong³ and Alan Friedman³, ¹Stanford University Medical Center, Palo Alto, CA, ²Albany Medical College, Albany, NY, ³AbbVie Inc., North Chicago, IL
Background/Purpose: Upadacitinib (UPA, ABT-494) is a selective, oral JAK-1 inhibitor studied in two phase 2 randomized controlled trials (RCTs) in patients (pts) with rheumatoid arthritis…
Abstract Number: 204 • 2016 ACR/ARHP Annual Meeting
The Safety and Efficacy of Allopurinol Dose Escalation in People with Gout, a Randomised Controlled Trial
Lisa K. Stamp¹, Peter T. Chapman², Murray Barclay³, Anne Horne⁴, Christopher Frampton¹, Paul Tan⁵, Jill Drake⁶ and Nicola Dalbeth⁵, ¹University of Otago, Christchurch, New Zealand, ²Christchurch Hospital, Christchurch, New Zealand, ³Medicine, University of Otago, Christchurch, New Zealand, ⁴Department of Medicine, University of Auckland, Auckland, New Zealand, ⁵University of Auckland, Auckland, New Zealand, ⁶Rheumatology, Immunology and Allergy, Christchurch Hospital, Christchurch, New Zealand
Background/Purpose: Allopurinol is the most widely used urate lowering therapy. Many patients on allopurinol fail to achieve target serum urate (SU), in part due to…
Abstract Number: 206 • 2016 ACR/ARHP Annual Meeting
Renal Safety of Lesinurad: A Pooled Analysis of Phase III and Extension Studies
Robert Terkeltaub¹, Raymond Malamet², Kathleen Bos², Jingyi Li², David Goldfarb³, Michael Pillinger⁴, Diana Jalal⁵, Jia Hu⁶ and Kenneth Saag⁷, ¹Rheumatology, VA Medical Center, San Diego, CA, ²AstraZeneca Pharmaceuticals, Wilmington, DE, ³New York University School of Medicine, New York, NY, USA, New York, NY, ⁴Medicine/Rheumatology, NYU School of Medicine/NYU Hospital for Joint Diseases, New York, NY, ⁵University of Colorado Anschutz Medical Center, Aurora, CO, USA, Aurora, CO, ⁶Ardea Biosciences, Inc., San Diego, CA, ⁷University of Alabama at Birmingham, Birmingham, AL, USA, Birmingham, AL
Background/Purpose: Lesinurad is a selective uric acid reabsorption inhibitor approved in the United States and European Union at 200 mg daily dose in combination with…
Abstract Number: 398 • 2016 ACR/ARHP Annual Meeting
Predictors of Clinical Remission with Etanercept in Pediatric Patients with Extended Oligoarticular, Enthesitis-Related Arthritis and Psoriatic Arthritis: Findings from the Clipper Study
Nicolino Ruperto¹, Alessandro Consolaro², Gerd Horneff¹, Rubén Burgos-Vargas¹, Tamas Constantin¹, Ivan Foeldvari¹, Jelena Vojinovic¹, Joke Dehoorne¹, Violeta Vladislava Panaviene¹, Gordana Susic¹, Valda Stanevicha¹, Katarzyna Kobusinska¹, Zbigniew Zuber³, Richard Mouy¹, Ingrida Rumba-Rozenfelde¹, Pavla Dolezalová¹, Chantal Job-deslandre⁴, Nico M Wulffraat¹, Ronald Pedersen⁵, Jack F Bukowski⁶, Tina Hinnershitz⁷, Bonnie Vlahos⁸ and Alberto Martini⁹, ¹Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy, ²Istituto Giannina Gaslini, Genoa, Italy, ³St Louis Children’s Hospital ODS Rheumatology and Neurology, Krakow, Poland, ⁴Pediatria II, Reumatologia, PRINTO, Istituto Giannina Gaslini, Genoa, Italy, ⁵Department of Biostatistics, Pfizer, Collegeville, PA, ⁶Clinical Affairs, Pfizer, Collegeville, PA, ⁷Specialty Care MDG, Pfizer, Collegeville, PA, ⁸GIPB - Clinical Sciences, Pfizer, Collegeville, PA, ⁹PRINTO-IRCCS, Genoa, Italy
Background/Purpose: Etanercept (ETN) is approved in the EU for the treatment of children with juvenile idiopathic arthritis (JIA) categories of polyarticular, extended oligoarticular (eoJIA), enthesitis-related…
Abstract Number: 949 • 2016 ACR/ARHP Annual Meeting
Comparison of Treatment Response, Remission Rate and Drug Adherence in Polyarticular Juvenile Idiopathic Arthritis Patients Treated with Etanercept, Adalimumab or Tocilizumab
Gerd Horneff^1,2, Ariane Klein³, Kirsten Minden^4,5, Hans-Iko Huppertz⁶, Frank Weller-Heinemann⁷, Jasmin B. Kuemmerle-Deschner⁸, Johannes Peter Haas⁹ and Toni Hospach¹⁰, ¹Asklepios Klinik Zentrum für Allgemeine Paediatrie und Neonatologie, Sankt Augustin, Germany, ²Department of Pediatrics, Centre of Pediatric Rheumatology, Sankt Augustin, Germany, ³Center of Pediatrics and Neonatology, Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, ⁴Epidemiology, Charite, DRFZ, Berlin, Germany, ⁵Children’s University Hospital Charite/German Rheumatism Research Centre Berlin, Berlin, Germany, ⁶Klinikum Bremen-Mitte, Prof.-Hess-Kinderklinik, Bremen, Germany, ⁷Prof.-Hess-Kinderklinik, Bremen,, Berlin, Germany, ⁸Universitätsklinikum Tübingen, Klinik fuer Kinder- und Jugendmedizin, Tübingen, Germany, ⁹German Center for Pediatric and Adolescent Rheumatology, Garmisch-Partenkirchen, Germany, ¹⁰Pediatrics, Olgahospital, Klinikum Stuttgart, Stuttgard, Germany
Background/Purpose: Treatment response, remission rates and compliance in polyarticular JIA patients treated with adalimumab(ADA), etanercept(ETA), or tocilizumab(TCZ) were analyzed in clinical practice. Methods: Data from the German BIKER…
Abstract Number: 1672 • 2015 ACR/ARHP Annual Meeting
One-Year Safety of Sirukumab Monotherapy: Results from a Randomized, Double-Blind, Parallel-Group, Multicenter Study in Japanese Subjects with Moderate to Severe Rheumatoid Arthritis
Tsutomu Takeuchi¹, Hisashi Yamanaka², Masayoshi Harigai³, Ryo Tamamura⁴, Yuchi Kato⁴, Yoshifumi Ukyo⁴, Toshikazu Nakano⁴, Takayuki Ota⁴, Benjamin Hsu⁵ and Yoshiya Tanaka⁶, ¹Keio University School of Medicine, Tokyo, Japan, ²Dept. of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ³Dept of Pharmacovigilance, Tokyo Medical and Dental University, Tokyo, Japan, ⁴Janssen Pharmaceutical K.K., Tokyo, Japan, ⁵Janssen Research & Development, LLC, Spring House, PA, ⁶The First Dept. of Internal Medicine, University of Occupational & Environmental Health, Kitakyusyu, Japan
Background/Purpose: Interleukin-6 (IL-6) is a pleiotropic cytokine known for its proinflammatory functions. In rheumatoid arthritis (RA), increased concentrations of IL-6 may stimulate leukocyte recruitment to…
Abstract Number: 1483 • 2014 ACR/ARHP Annual Meeting
Efficacy and Safety of Baricitinib in Japanese Rheumatoid Arthritis Patients during a 52 Week Extension Phase
Yoshiya Tanaka¹, Kahaku Emoto², Zhihong Cai², Douglas E. Schlichting³, Terence Rooney³ and William Macias³, ¹University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²Eli Lilly Japan K.K., Kobe, Japan, ³Eli Lilly and Company, Indianapolis, IN
Background/Purpose Baricitinib (bari), an oral JAK1/JAK2 signaling inhibitor, was evaluated in a blinded phase 2b study for 12 weeks as a treatment for rheumatoid arthritis…
Abstract Number: 345 • 2012 ACR/ARHP Annual Meeting
Predictive Software-Based Mathematical Modeling: A Novel Approach to Development of Oral Therapies for Rheumatoid Arthritis – Validation in a Murine Collagen Induced Arthritis Model
Gurkirpal Singh¹, Robinson Vidva², Prashant Nair², Saumya Radhakrishnan², Pradeep Fernandes², Taher Abbasi², Canio Refino³, Jay Dela Cruz³ and Shireen Vali², ¹Gastroenterology/Hepatology, Stanford University School of Medicine, Palo Alto, CA, ²CellWorks Group, Saratoga, CA, ³InTouch Bio, Alameda, CA
Background/Purpose: Rheumatoid Arthritis (RA) involves complex interactions of multiple cell systems, cytokines and mediators, and interlinked signaling. While molecularly-targeted therapies manipulate specific interactions, it is…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].